Population-Based Impact of Pneumococcal Conjugate Vaccine in Young Children
Published in the journal Pediatrics, this study aims to determine the population impact of pneumococcal conjugate vaccine (PCV) on pneumococcal-related diseases, including pneumonia and otitis media by measuring annual rates of medical visits for pneumococcal-related diseases (pneumococcal and nonspecific pneumonia and invasive disease; otitis media) and pneumococcal-unrelated diseases (other acute respiratory illnesses). Disease rates before (1995–2000 in Tennessee; 1998–2000 in New York) and after (2000–2002) PCV licensure were calculated for children aged <2 years (eligible for PCV) and those 3 to 5 years (not routinely given PCV). Because annual variations should affect both age groups similarly and vaccine-related outcomes should preferentially decline in younger children, ratios (<2:3–5 years) of disease rates before and after PCV licensure were compared. Expected disease rates were calculated for children aged <2 years in each postvaccine year. The difference between observed and expected disease rates was the estimated vaccine effect.
Author(s): Poehling K, Lafleur BJ, Szilagyi PG, et al.
Download file (English)
104 KB PDF (Located at pediatrics.aappublications.org)
Citation: Poehling K, Lafleur BJ, Szilagyi PG, et al. Population-based Impact of Pneumococcal Conjugate Vaccine in Young Children. Pediatrics. 2004;114(3):755-761.